Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $17.00 target price on the stock.

Several other research firms also recently weighed in on IMUX. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, February 10th. HC Wainwright assumed coverage on shares of Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Price Performance

Shares of Immunic stock opened at $1.26 on Thursday. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11. The business’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.26. The company has a market capitalization of $113.32 million, a P/E ratio of -1.02 and a beta of 1.87.

Hedge Funds Weigh In On Immunic

Several large investors have recently made changes to their positions in IMUX. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the last quarter. State Street Corp lifted its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter worth $50,000. Finally, HB Wealth Management LLC acquired a new stake in shares of Immunic during the fourth quarter worth $81,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.